Mediterranean Diet Improves High-Density Lipoprotein Function in High-Cardiovascular-Risk Individuals

Circulation

Volumn 135, Issue 7, 2017, Pages 633-643

  Hernáez, Álvaro ^a,d,e,h   Castañer, Olga ^a,h   Elosua, Roberto ^b   Pintó, Xavier ^h,i   Estruch, Ramón ^g,h   Salas Salvadó, Jordi ^h,j   Corella, Dolores ^h,k   Arós, Fernando ^h,l   Serra Majem, Lluis ^h,m   Fiol, Miquel ^h,n   Ortega Calvo, Manuel ^h,o   Ros, Emilio ^h,p   Martínez González, Miguel Ángel ^h   De La Torre, Rafael ^a,c,h   López Sabater, M Carmen ^f,g,h   Fitó, Montserrat ^a,h  

^a Cardiovascular Risk and Nutrition Research Group   (United States)

^b Cardiovascular Epidemiology and Genetics Research Group   (United States)

^c Neurosciences Research Group   (United States)

^d HOSPITAL DEL MAR   (Spain)

^e Program in Food Sciences and Nutrition   (United States)

^f Department of Nutrition and Bromatology   (United States)

^g UNIVERSITY OF BARCELONA   (Spain)

^h INSTITUTO DE SALUD CARLOS III   (Spain)

ⁱ HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^j UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^k UNIVERSITY OF VALENCIA   (Spain)

^l HOSPITAL TXAGORRITXU   (Spain)

^m UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

ⁿ HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^o Centro de Salud Las Palmeritas   (Spain)

^p UNIVERSITY OF NAVARRA   (Spain)

more..

Author keywords

antioxidant; diet; lipids; lipoproteins, HDL; randomized controlled trial publication type

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; FATTY ACID; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; PARAOXONASE 1 ARYLESTERASE; PROTEIN; UNCLASSIFIED DRUG; VIRGIN OLIVE OIL;

AGED; ANTIOXIDANT ACTIVITY; ANTIOXIDANT ASSAY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL ESTERIFICATION; CHOLESTEROL TRANSPORT; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIETARY INTAKE; ENZYME ACTIVITY; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; LIPID COMPOSITION; LIPID DIET; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MEDITERRANEAN DIET; NUT; OXIDATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; THERAPY EFFECT; TRADITIONAL MEDITERRANEAN DIET; TREATMENT OUTCOME; VASODILATATION; DIET THERAPY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIET, MEDITERRANEAN; HUMANS; LIPIDS; LIPOPROTEINS, HDL; MIDDLE AGED; RISK FACTORS;

EID: 85012928579     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.023712     Document Type: Article

References (47)

1. Martinez-Gonzalez MA, Bes-Rastrollo M. Dietary patterns, Mediterranean diet, and cardiovascular disease. Curr Opin Lipidol. 2014;25:20-26. doi: 10. 1097/MOL. 0000000000000044.
2. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pintó X, Basora J, Muñoz MA, Sorlí JV, Martínez JA, Martínez-González MA; PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368:1279-1290. doi: 10. 1056/NEJMoa1200303.
3. Ros E, Martínez-González MA, Estruch R, Salas-Salvadó J, Fitó M, Martínez JA, Corella D. Mediterranean diet and cardiovascular health: Teachings of the PREDIMED study. Adv Nutr. 2014;5:330S-336S. doi: 10. 3945/an. 113. 005389.
4. Mena MP, Sacanella E, Vazquez-Agell M, Morales M, Fitó M, Escoda R, Serrano-Martínez M, Salas-Salvadó J, Benages N, Casas R, Lamuela-Raventós RM, Masanes F, Ros E, Estruch R. Inhibition of circulating immune cell activation: A molecular antiinflammatory effect of the Mediterranean diet. Am J Clin Nutr. 2009;89:248-256. doi: 10. 3945/ajcn. 2008. 26094.
5. Mitjavila MT, Fandos M, Salas-Salvadó J, Covas MI, Borrego S, Estruch R, Lamuela-Raventós R, Corella D, Martínez-Gonzalez MÁ, Sánchez JM, Bulló M, Fitó M, Tormos C, Cerdá C, Casillas R, Moreno JJ, Iradi A, Zaragoza C, Chaves J, Sáez GT. The Mediterranean diet improves the systemic lipid and DNA oxidative damage in metabolic syndrome individuals: A randomized, controlled, trial. Clin Nutr. 2013;32:172-178. doi: 10. 1016/j. clnu. 2012. 08. 002.
6. Castañer O, Corella D, Covas MI, Sorlí JV, Subirana I, Flores-Mateo G, Nonell L, Bulló M, de la Torre R, Portolés O, Fitó M; PREDIMED Study Investigators. In vivo transcriptomic profile after a Mediterranean diet in high-cardiovascular risk patients: A randomized controlled trial. Am J Clin Nutr. 2013;98:845-853. doi: 10. 3945/ ajcn. 113. 060582.
7. Martinez-Gonzalez MA, Ruiz-Canela M, Hruby A, Liang L, Trichopoulou A, Hu FB. Intervention trials with the Mediterranean diet in cardiovascular prevention: understanding potential mechanisms through metabolomic profiling. J Nutr. 2016;146:913S-919S.
8. Estruch R, Martínez-González MA, Corella D, Salas-Salvadó J, Ruiz-Gutiérrez V, Covas MI, Fiol M, Gómez-Gracia E, López-Sabater MC, Vinyoles E, Arós F, Conde M, Lahoz C, Lapetra J, Sáez G, Ros E; PREDIMED Study Investigators. Effects of a Mediterraneanstyle diet on cardiovascular risk factors: A randomized trial. Ann Intern Med. 2006;145:1-11.
9. Solá R, Fitó M, Estruch R, Salas-Salvadó J, Corella D, de La Torre R, Muñoz MA, López-Sabater Mdel C, Martínez-González MA, Arós F, Ruiz-Gutierrez V, Fiol M, Casals E, Wärnberg J, Buil-Cosiales P, Ros E, Konstantinidou V, Lapetra J, Serra-Majem L, Covas MI. Effect of a traditional Mediterranean diet on apolipoproteins B, A-I, and their ratio: A randomized, controlled trial. Atherosclerosis. 2011;218:174-180. doi: 10. 1016/j. Atherosclerosis. 2011. 04. 026.
10. Rosenson RS, Brewer HB Jr, Ansell B, Barter P, Chapman MJ, Heinecke JW, Kontush A, Tall AR, Webb NR. Translation of highdensity lipoprotein function into clinical practice: current prospects and future challenges. Circulation. 2013;128:1256-1267. doi: 10. 1161/CIRCULATIONAHA. 113. 000962.
11. Hernáez Á, Fernández-Castillejo S, Farràs M, Catalán Ú, Subirana I, Montes R, Solà R, Muñoz-Aguayo D, Gelabert-Gorgues A, Díaz-Gil Ó, Nyyssönen K, Zunft HJ, de la Torre R, Martín-Peláez S, PedretA, Remaley AT, Covas MI, Fitó M. Olive oil polyphenols enhance high-density lipoprotein function in humans: A randomized controlled trial. Arterioscler Thromb Vasc Biol. 2014;34:2115-2119. doi: 10. 1161/ATVBAHA. 114. 303374.
12. Sola R, Motta C, Maille M, Bargallo MT, Boisnier C, Richard JL, Jacotot B. Dietary monounsaturated fatty acids enhance cholesterol efflux from human fibroblasts: relation to fluidity, phospholipid fatty acid composition, overall composition, and size of HDL3. Arterioscler Thromb. 1993;13:958-966.
13. McEneny J, Wade L, Young IS, Masson L, Duthie G, McGinty A, McMaster C, Thies F. Lycopene intervention reduces inflammation and improves HDL functionality in moderately overweight middle-aged individuals. J Nutr Biochem. 2013;24:163-168. doi: 10. 1016/j. jnutbio. 2012. 03. 015.
14. Tanaka N, Ishida T, Nagao M, Mori T, Monguchi T, Sasaki M, Mori K, Kondo K, Nakajima H, Honjo T, Irino Y, Toh R, Shinohara M, Hirata K. Administration of high dose eicosapentaenoic acid enhances anti-inflammatory properties of high-density lipoprotein in Japanese patients with dyslipidemia. Atherosclerosis. 2014;237:577-583. doi: 10. 1016/j. Atherosclerosis. 2014. 10. 011.
15. Martínez-González MÁ, Corella D, Salas-Salvadó J, Ros E, Covas MI, Fiol M, Wärnberg J, Arós F, Ruíz-Gutiérrez V, Lamuela-Raventós RM, Lapetra J, Muñoz MÁ, Martínez JA, Sáez G, Serra-Majem L, Pintó X, Mitjavila MT, Tur JA, Portillo MP, Estruch R; PREDIMED Study Investigators. Cohort profile: design and methods of the PREDIMED study. Int J Epidemiol. 2012;41:377-385. doi: 10. 1093/ije/dyq250.
16. Hernáez Á, Remaley AT, Farràs M, Fernández-Castillejo S, Subirana I, Schröder H, Fernández-Mampel M, Muñoz-Aguayo D, Sampson M, Solà R, Farré M, de la Torre R, López-Sabater MC, Nyyssönen K, Zunft HJ, Covas MI, Fitó M. Olive oil polyphenols decrease LDL concentrations and LDL atherogenicity in men in a randomized controlled trial. J Nutr. 2015;145:1692-1697. doi: 10. 3945/jn. 115. 211557.
17. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127-135. doi: 10. 1056/NEJMoa1001689.
18. Farràs M, Castañer O, Martín-Peláez S, Hernáez Á, Schröder H, Subirana I, Muñoz-Aguayo D, Gaixas S, Torre Rde L, Farré M, Rubió L, Díaz Ó, Fernández-Castillejo S, Solà R, Motilva MJ, Fitó M. Complementary phenol-enriched olive oil improves HDL characteristics in hypercholesterolemic subjects: A randomized, double-blind, crossover, controlled trial: The VOHF study. Mol Nutr Food Res. 2015;59:1758-1770. doi: 10. 1002/ mnfr. 201500030.
19. Patel PJ, Khera AV, Jafri K, Wilensky RL, Rader DJ. The antioxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. J Am Coll Cardiol. 2011;58:2068-2075. doi: 10. 1016/j. jacc. 2011. 08. 030.
20. Osto E, Doytcheva P, Corteville C, Bueter M, Dörig C, Stivala S, Buhmann H, Colin S, Rohrer L, Hasballa R, Tailleux A, Wolfrum C, Tona F, Manz J, Vetter D, Spliethoff K, Vanhoutte PM, Landmesser U, Pattou F, Staels B, Matter CM, Lutz TA, Lüscher TF. Rapid and body weight-independent improvement of endothelial and highdensity lipoprotein function after Roux-en-Y gastric bypass: role of glucagon-like peptide-1. Circulation. 2015;131:871-881. doi: 10. 1161/CIRCULATIONAHA. 114. 011791.
21. Takata K, Imaizumi S, Kawachi E, Suematsu Y, Shimizu T, Abe S, Matsuo Y, Tsukahara H, Noda K, Yahiro E, Zhang B, Uehara Y, Miura S, Saku K. Impact of cigarette smoking cessation on highdensity lipoprotein functionality. Circ J. 2014;78:2955-2962.
22. Covas MI, Nyyssönen K, Poulsen HE, Kaikkonen J, Zunft HJ, Kiesewetter H, Gaddi A, de la Torre R, Mursu J, Bäumler H, Nascetti S, Salonen JT, Fitó M, Virtanen J, Marrugat J; EUROLIVE Study Group. The effect of polyphenols in olive oil on heart disease risk factors: A randomized trial. Ann Intern Med. 2006;145:333-341.
23. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2014. http://www. r-project. org/. Accessed December 5, 2016.
24. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L. Cholesterol efflux and atheroprotection: Advancing the concept of reverse cholesterol transport. Circulation. 2012;125:1905-1919. doi: 10. 1161/CIRCULATIONAHA. 111. 066589.
25. Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ, Yuhanna IS, Rader DR, de Lemos JA, Shaul PW. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371:2383-2393. doi: 10. 1056/NEJMoa1409065.
26. Larrede S, Quinn CM, Jessup W, Frisdal E, Olivier M, Hsieh V, Kim MJ, Van Eck M, Couvert P, Carrie A, Giral P, Chapman MJ, Guerin M, Le Goff W. Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent. Arterioscler Thromb Vasc Biol. 2009;29:1930-1936. doi: 10. 1161/ATVBAHA. 109. 194548.
27. Bonnefont-Rousselot D, Motta C, Khalil AO, Sola R, La Ville AE, Delattre J, Gardès-Albert M. Physicochemical changes in human high-density lipoproteins (HDL) oxidized by gamma radiolysis-generated oxyradicals: effect on their cholesterol effluxing capacity. Biochim Biophys Acta. 1995;1255:23-30.
28. Farràs M, Valls RM, Fernández-Castillejo S, Giralt M, Solà R, Subirana I, Motilva MJ, Konstantinidou V, Covas MI, Fitó M. Olive oil polyphenols enhance the expression of cholesterol efflux related genes in vivo in humans: A randomized controlled trial. J Nutr Biochem. 2013;24:1334-1339. doi: 10. 1016/j. jnutbio. 2012. 10. 008.
29. Hovingh GK, Hutten BA, Holleboom AG, Petersen W, Rol P, Stalenhoef A, Zwinderman AH, de Groot E, Kastelein JJ, Kuivenhoven JA. Compromised LCAT function is associated with increased atherosclerosis. Circulation. 2005;112:879-884. doi: 10. 1161/ CIRCULATIONAHA. 105. 540427.
30. Wang K, Subbaiah PV. Importance of the free sulfhydryl groups of lecithin-cholesterol acyltransferase for its sensitivity to oxidative inactivation. Biochim Biophys Acta. 2000;1488:268-277.
31. Daniels JA, Mulligan C, McCance D, Woodside JV, Patterson C, Young IS, McEneny J. A randomised controlled trial of increasing fruit and vegetable intake and how this influences the carotenoid concentration and activities of PON-1 and LCAT in HDL from subjects with type 2 diabetes. Cardiovasc Diabetol. 2014;13:16. doi: 10. 1186/1475-2840-13-16.
32. Barter PJ, Nicholls SJ, Kastelein JJ, Rye KA. Is cholesteryl ester transfer protein inhibition an effective strategy to reduce cardiovascular risk? CETP inhibition as a strategy to reduce cardiovascular risk: The pro case. Circulation. 2015;132:423-432. doi: 10. 1161/CIRCULATIONAHA. 114. 014025.
33. McLain JH, Alsterda AJ, Arora RR. Cholesteryl ester transfer protein inhibitors: Trials and tribulations [published online ahead of print August 10, 2016]. J Cardiovasc Pharmacol Ther. doi: 10. 1177/1074248416662349. http://journals. sagepub. com/ doi/full/10. 1177/1074248416662349. Accessed December 5, 2016.
34. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, Rahmani S, Mottahedeh R, Dave R, Reddy ST, Fogelman AM. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than highdensity lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003;108:2751-2756. doi: 10. 1161/01. CIR. 0000103624. 14436. 4B.
35. Tang WH, Hartiala J, Fan Y, Wu Y, Stewart AF, Erdmann J, Kathiresan S, Roberts R, McPherson R, Allayee H, Hazen SL; CARDIoGRAM Consortium. Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arterioscler Thromb Vasc Biol. 2012;32:2803-2812. doi: 10. 1161/ATVBAHA. 112. 253930.
36. Kunutsor SK, Bakker SJ, James RW, Dullaart RP. Serum paraoxonase-1 activity and risk of incident cardiovascular disease: The PREVEND study and meta-analysis of prospective population studies. Atherosclerosis. 2016;245:143-154. doi: 10. 1016/j. Atherosclerosis. 2015. 12. 021.
37. Aviram M, Vaya J. Paraoxonase 1 activities, regulation, and interactions with atherosclerotic lesion. Curr Opin Lipidol. 2013;24:339-344. doi: 10. 1097/MOL. 0b013e32835ffcfd.
38. Hernáez A, Farràs M, Fitó M. Olive oil phenolic compounds and high-density lipoprotein function. Curr Opin Lipidol. 2016;27:47-53 doi: 10. 1097/MOL. 0000000000000261.
39. Besler C, Lüscher TF, Landmesser U. Molecular mechanisms of vascular effects of high-density lipoprotein: Alterations in cardiovascular disease. EMBO Mol Med. 2012;4:251-268. doi: 10. 1002/emmm. 201200224.
40. Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, Bahlmann FH, Mueller M, Horváth T, Doerries C, Heinemann M, Flemmer S, Markowski A, Manes C, Bahr MJ, Haller H, von Eckardstein A, Drexler H, Landmesser U. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation. 2010;121:110-122. doi: 10. 1161/CIRCULATIONAHA. 108. 836346.
41. Sang H, Yao S, Zhang L, Li X, Yang N, Zhao J, Zhao L, Si Y, Zhang Y, Lv X, Xue Y, Qin S. Walk-run training improves the anti-inflammation properties of high-density lipoprotein in patients with metabolic syndrome. J Clin Endocrinol Metab. 2015;100:870-879. doi: 10. 1210/jc. 2014-2979.
42. Parks EJ, Krauss RM, Christiansen MP, Neese RA, Hellerstein MK. Effects of a low-fat, high-carbohydrate diet on VLDLtriglyceride assembly, production, and clearance. J Clin Invest. 1999;104:1087-1096. doi: 10. 1172/JCI6572.
43. Del Gobbo LC, Falk MC, Feldman R, Lewis K, Mozaffarian D. Effects of tree nuts on blood lipids, apolipoproteins, and blood pressure: systematic review, meta-analysis, and dose-response of 61 controlled intervention trials. Am J Clin Nutr. 2015;102:1347-1356. doi: 10. 3945/ajcn. 115. 110965.
44. Sparks DL, Davidson WS, Lund-Katz S, Phillips MC. Effects of the neutral lipid content of high density lipoprotein on apolipoprotein A-I structure and particle stability. J Biol Chem. 1995;270:26910-26917.
45. Sung KC, Ryu S, Wild SH, Byrne CD. An increased high-density lipoprotein cholesterol/apolipoprotein A-I ratio is associated with increased cardiovascular and all-cause mortality. Heart. 2015;101:553-558. doi: 10. 1136/heartjnl-2014-306784.
46. Akinkuolie AO, Paynter NP, Padmanabhan L, Mora S. High-density lipoprotein particle subclass heterogeneity and incident coronary heart disease. Circ Cardiovasc Qual Outcomes. 2014;7:55-63. doi: 10. 1161/CIRCOUTCOMES. 113. 000675.
47. Damasceno NR, Sala-Vila A, Cofán M, Pérez-Heras AM, Fitó M, Ruiz-Gutiérrez V, Martínez-González MÁ, Corella D, Arós F, Estruch R, Ros E. Mediterranean diet supplemented with nuts reduces waist circumference and shifts lipoprotein subfractions to a less atherogenic pattern in subjects at high cardiovascular risk. Atherosclerosis. 2013;230:347-353. doi: 10. 1016/j. Atherosclerosis. 2013. 08. 014.